Skip to Main Content

Paper Details

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Blood
16
2023
Author NameAffiliation
Marlise R LuskinDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Jerome RitzDana-Farber Cancer Institute
Catherine J WuDana-Farber Cancer Institute
Daniel J DeAngeloDana-Farber Cancer Institute
Donna NeubergDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
  • 1 - 7

Datasets

Release 1.2